Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery

NCT06762782 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

276

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)
Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation

Interventions

DRUG: Postoperative adjuvant lenvatinib
OTHER: Supportive care measures

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]